on Theranexus (EPA:ALTHX)
THX Pharma Publishes Letter to Shareholders
March 25, 2026, Lyon – THX Pharma, a biopharmaceutical firm, has published its letter to shareholders. The company specializes in treatments for rare neurological diseases. The letter is accessible on the Theranexus website under the Shareholders/Financial Documents section.
THX Pharma invites shareholders to register for updates and receive all company communications. This initiative ensures stakeholders remain informed on the firm's activities and developments.
THX Pharma is known for developing innovative treatments such as TX01, aimed at Gaucher disease and Niemann-Pick disease type C, and Batten-1 targeting juvenile Batten disease. Both products are under licensing agreements with international partners for global distribution.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Theranexus news